下呼吸道微生物群与肺癌患者的检查点抑制剂肺炎有关。
Lower respiratory tract microbiome is associated with checkpoint inhibitor pneumonitis in lung cancer patients.
作者信息
Zhang Dongming, Fan Junping, Liu Xiaoyan, Gao Xiaoxing, Zhou Qing, Zhao Jing, Xu Yan, Zhong Wei, Oh In-Jae, Chen Minjiang, Wang Mengzhao
机构信息
Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Department of Internal Medicine, Chonnam National University Medical School and Hwasun Hospital, Jeonnam, Republic of Korea.
出版信息
Transl Lung Cancer Res. 2024 Nov 30;13(11):3189-3201. doi: 10.21037/tlcr-24-853. Epub 2024 Nov 27.
BACKGROUND
The gut microbiome is associated with the occurrence and severity of immune-related adverse events (irAEs) in cancer patients undergoing immunotherapy. However, the relationship between the lower respiratory tract (LRT) microbiome and checkpoint inhibitor pneumonitis (CIP) in lung cancer patients who underwent immunotherapy is unclear. The aim of the present study was to investigate the associations between the LRT microbiome and CIP in lung cancer patients receiving immunotherapy.
METHODS
This retrospective study included lung cancer patients who received immunotherapy and had metagenomic next-generation sequencing (mNGS) results of LRT specimens [bronchoalveolar lavage fluid (BALF)]. Based on their final diagnosis, the patients were allocated to either the CIP group or the non-CIP group. We conducted an exploratory analysis of the LRT microbiome in the CIP and non-CIP patients, delineating the microbial composition, and comparing the differences between the two groups.
RESULTS
In total, 52 lung patients were included in the study, of whom 33 were allocated to the CIP group and 19 to the non-CIP group. The alpha- and beta-diversity analyses revealed no significant differences between the two groups. In the CIP group, the dominant phyla were (41.7%), (18.2%), and (16.3%). In the non-CIP group, the dominant phyla were (38.2%), (18.4%), and (17.8%). Notably, the relative abundance of the phylum (P<0.001) and phylum (P=0.01) was significantly higher in the CIP group than the non-CIP group.
CONCLUSIONS
The elevated relative abundance of the and phyla in the LRT samples is associated with CIP in lung cancer patients.
背景
肠道微生物群与接受免疫治疗的癌症患者免疫相关不良事件（irAEs）的发生和严重程度有关。然而，接受免疫治疗的肺癌患者下呼吸道（LRT）微生物群与检查点抑制剂肺炎（CIP）之间的关系尚不清楚。本研究的目的是调查接受免疫治疗的肺癌患者LRT微生物群与CIP之间的关联。
方法
这项回顾性研究纳入了接受免疫治疗并具有LRT标本[支气管肺泡灌洗（BALF）]宏基因组下一代测序（mNGS）结果的肺癌患者。根据最终诊断，将患者分为CIP组或非CIP组。我们对CIP和非CIP患者的LRT微生物群进行了探索性分析，描述了微生物组成，并比较了两组之间的差异。
结果
本研究共纳入52例肺癌患者，其中33例被分配到CIP组，19例被分配到非CIP组。α和β多样性分析显示两组之间无显著差异。在CIP组中，优势菌门为（41.7%）、（18.2%）和（16.3%）。在非CIP组中，优势菌门为（38.2%）、（18.4%）和（17.8%）。值得注意的是，CIP组中门（P<0.001）和门（P=0.01）的相对丰度显著高于非CIP组。
结论
LRT样本中门和门的相对丰度升高与肺癌患者的CIP有关。
Zotero 插件